In order to reprogram readily available cells into specific immune cells that fight various diseases, one must know the ...

The action plays out like a twin-stick shooter, my parasite's undulating "secretors" functioning as guns and my host's ...

Scientists are unraveling the role of senescent cells in a common form of epilepsy, and it could point to new treatments.

Published on January 6, 2026, in Volume 2 of the Immunity & Inflammation journal, the review begins by underscoring Professor Taniguchi's ...

Cells that are about to die send a signal to an executioner protein, but sometimes, those cells can fight back and regenerate ...

Even with breakthroughs, treatment for advanced squamous cell carcinoma is more complex. Patients often need more than one treatment. Many patients with this advanced cancer are cared for by a team of ...

AbbVie and RemeGen are collaborating on RC148, a novel PD-1/VEGF-targeted bispecific antibody already being developed as a ...

A ₹3.5 crore Madhya Pradesh-funded study on cow dung and urine as cancer treatment raises questions over scientific validity, ...

AbbVie & RemeGen enter exclusive licensing agreement to develop novel bispecific antibody for advanced solid tumours: North Chicago, Illinois Tuesday, January 13, 2026, 14:00 Hrs ...

(Yicai) Jan. 13 -- Shares of RemeGen surged by their daily trading limit in Shanghai after the Chinese drugmaker granted US ...

US pharma major AbbVie and China’s RemeGen today announced an exclusive licensing agreement for the development, ...

AbbVie (NYSE: ABBV) and RemeGen today announced an exclusive licensing agreement for the development, manufacturing and commercialization of RC148, a novel investigational Programmed Cell Death-1 ...